Zymeworks IncChange company Symbol lookupSelect an option...ZYME Zymeworks IncNYC American Strategic Investment CoMDV Modiv IncSBIG springbig Holdings IncKBNT Kubient IncFGF FG Financial Group IncNVNO enVVeno Medical CorpBROGW Brooge Holdings Equity Warrants Expiring 20 Dec 2024 *W EXP 12/20/2024IOVA Iovance Biotherapeutics IncPUYI Puyi IncGo
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas with an emphasis on developing ADC and multi-specific antibody therapeutics (MSAT) candidates. Its pipeline of preclinical product candidates includes two lead programs, ZW191 and ZW17.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| May 8, 2023 | Q1 2023 Earnings Release | -$0.36 | -$0.88 to -$0.02 | -$1.18 |
| March 7, 2023 | Q4 2022 Earnings Release | $4.65 | $3.88 to $5.50 | -$0.76 |
| November 8, 2022 | Q3 2022 Earnings Release | -$0.72 | -$1.15 to -$0.74 | -$1.17 |
| August 4, 2022 | Q2 2022 Earnings Release | -$0.97 | -$1.14 to -$0.78 | -$1.31 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.